Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 20,607 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

NCT01311661
View directory record Official record
Conditions
Asthma
Interventions
Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
12
States / cities
Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

NCT00614042
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL)
Interventions
TRU-016 (anti-CD37 protein therapeutic)
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Birmingham, Alabama • Augusta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 4 Interventional

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

NCT01283425
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Quadrivalent influenza vaccine, Ofatumumab, iDMT
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 4:19 PM EDT
Terminated Not applicable Interventional Results available

Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT03772717
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
5 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

NCT01734850
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
Drug · Biological
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

NCT04531813
View directory record Official record
Conditions
Hypersensitivity
Interventions
Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

NCT00070382
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

NCT00344123
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir/Ritonavir, Rosuvastatin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Engagement in HIV Care for High-risk Women

NCT03081559
View directory record Official record
Conditions
HIV/AIDS, Adherence, Medication
Interventions
Healthy Divas
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 21, 2026, 4:19 PM EDT
Completed No phase listed Observational

Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite

NCT03279185
View directory record Official record
Conditions
HIV/AIDS
Interventions
Not listed
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 21, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

NCT02337517
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Laboratory Biomarker Analysis, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 21, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

NCT07382817
View directory record Official record
Conditions
Neoplasms
Interventions
JV-394
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes

NCT04190368
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Team Clinic Care, Standard Care
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01729091
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Use of Rosiglitazone to Treat Asthma

NCT00614874
View directory record Official record
Conditions
Asthma
Interventions
rosiglitazone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 21, 2026, 4:19 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

NCT04176718
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Interventions
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Andrew Yee, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
6
States / cities
Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 21, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

NCT00003910
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Methotrexate, Prednisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
68
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

Two Approaches to Routine HIV Testing in a Hospital Emergency Department

NCT01258582
View directory record Official record
Conditions
HIV Infections
Interventions
Oral HIV screening, Fingerstick HIV screening
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

NCT00670423
View directory record Official record
Conditions
Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
Interventions
Tacrolimus, Sirolimus, Bortezomib
Drug
Lead sponsor
Jennifer E. Schwartz
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT01282476
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Panobinostat with Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 21, 2026, 4:19 PM EDT